2022
Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients
Banach DB, Lopez‐Verdugo F, Sanchez‐Garcia J, Tran A, Gomez‐Llerena A, Munoz‐Abraham A, Bertacco A, Valentino PL, Yoo P, Dembry L, Mulligan DC, Ekong UD, Emre SH, Rodriguez‐Davalos M. Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients. Transplant Infectious Disease 2022, 24: e13941. PMID: 35989545, DOI: 10.1111/tid.13941.Peer-Reviewed Original ResearchConceptsSurgical site infectionLiver transplant recipientsLiver transplantationBiliary complicationsGraft recipientsTransplant recipientsSite infectionRisk factorsOutcomes of SSIPediatric liver transplant recipientsLong-term graftPediatric liver transplantationRetrospective descriptive analysisPrimary endpointHospital daysPatient agePediatric populationPatient survivalSignificant causeComplicationsPatientsRecipientsOutcomesInfectionIncidence
2021
Developing simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy
Wilk AR, Booker SE, Stewart DE, Wiseman A, Gauntt K, Mulligan D, Formica RN. Developing simultaneous liver‐kidney transplant medical eligibility criteria while providing a safety net: A 2‐year review of the OPTN's allocation policy. American Journal Of Transplantation 2021, 21: 3593-3607. PMID: 34254434, DOI: 10.1111/ajt.16761.Peer-Reviewed Original ResearchConceptsMedical Eligibility CriteriaEligibility criteriaLiver transplantPatient/graft survivalWaitlist mortality rateDeceased donor kidneysLiver recipientsSLK candidatesSLK transplantsGraft survivalRenal impairmentPosttransplant outcomesDonor kidneysTransplant ratesTransplant volumeMortality rateTransplantKidneySignificant differencesRecipientsSubsequent increaseLiver dataCriteriaImpairmentSLKBile Microbiota in Liver Transplantation: Proof of Concept Using Gene Amplification in a Heterogeneous Clinical Scenario
D'Amico F, Bertacco A, Finotti M, Di Renzo C, Rodriguez-Davalos MI, Gondolesi GE, Cillo U, Mulligan D, Geibel J. Bile Microbiota in Liver Transplantation: Proof of Concept Using Gene Amplification in a Heterogeneous Clinical Scenario. Frontiers In Surgery 2021, 8: 621525. PMID: 33796547, PMCID: PMC8009296, DOI: 10.3389/fsurg.2021.621525.Peer-Reviewed Original ResearchBile microbiotaLiver donorsBiliary tract diseaseCommon bile ductGene amplificationRibosomal RNA gene amplificationLiver recipientsLiver transplantationPediatric recipientsLiver proceduresBiliary tractBile ductRecipient patientsTract diseaseBile samplesHeterogeneous cohortClinical scenariosBileSterile wayPCR sequencingPatientsRecipientsMicrobiotaTransplantationGallbladder
2019
Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death
Valentino PL, Emre S, Geliang G, Li L, Deng Y, Mulligan D, Rodriguez-Davalos M. Frequency of whole-organ in lieu of split-liver transplantation over the last decade: Children experienced increased wait time and death. American Journal Of Transplantation 2019, 19: 3114-3123. PMID: 31152483, DOI: 10.1111/ajt.15481.Peer-Reviewed Original ResearchConceptsAdult recipientsTransplantation Network/United NetworkNumber of allograftsOrgan Sharing dataSplit-liver transplantationCareful patient selectionDeceased donor liversNumber of LTLT graftSLT recipientsUnderwent LTWLT recipientsPediatric candidatesPatient selectionDonor liversOrgan utilizationUnited NetworkOrgan shortageOrgan procurementSmall childrenRecipientsTransplantation
2018
Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient
Fu W, Merola J, Malinis M, Lacy J, Barbieri A, Liapakis AH, Mulligan DC, Yoo PS. Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient. Transplant Infectious Disease 2018, 20: e12966. PMID: 30014622, DOI: 10.1111/tid.12966.Peer-Reviewed Case Reports and Technical NotesConceptsHuman herpesvirus 8 infectionHepatic Kaposi sarcomaKaposi's sarcomaTransplant recipientsAdult liver transplant recipientsRegression of KSSplit liver transplantAcute cellular rejectionLiver transplant recipientsSuccessful therapeutic strategiesAllograft functionCellular rejectionLiver transplantSeropositive donorsSuccessful treatmentLiposomal doxorubicinTherapeutic strategiesRecipientsSarcomaInfectionTreatmentImmunosuppressionPatientsMalignancyTransplant
2016
De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient
Cohen E, Mulligan D, Kulkarni S, Tichy E. De Novo Belatacept in a Human Immunodeficiency Virus–Positive Kidney Transplant Recipient. American Journal Of Transplantation 2016, 16: 2753-2757. PMID: 27137752, DOI: 10.1111/ajt.13852.Peer-Reviewed Original ResearchConceptsRenal transplant recipientsTransplant recipientsHuman immunodeficiency virus–positive kidney transplant recipientHIV-positive renal transplant recipientsPositive renal transplant recipientsHIV-positive Black menActive antiretroviral agentsKidney transplant recipientsNew-onset diabetesHuman immunodeficiency virusImmunosuppressive regimensFirst transplantAntiretroviral agentsCalcineurin inhibitorsImmunodeficiency virusKidney donorsDrug interactionsTransplantRecipientsBlack menSuccessful casesDe novoBelataceptHypertensionHyperlipidemia
2012
Baseline Biopsy Findings and Clinical Outcomes in Recipients of Kidneys from Standard Criteria Donors (SCD) with Acute Kidney Injury (AKI)
Reddy K, Smith M, Chakkera H, Moss A, Mulligan D, Khamash H, Hewitt W, Katariya N, Heilman R. Baseline Biopsy Findings and Clinical Outcomes in Recipients of Kidneys from Standard Criteria Donors (SCD) with Acute Kidney Injury (AKI). Transplantation 2012, 94: 341. DOI: 10.1097/00007890-201211271-00631.Peer-Reviewed Original ResearchSingle Center Review of Seroconversion Rate and Clinical Outcomes of Kidney Transplant Recipients from Center for Disease Control (CDC) High Risk Donors
Bodner J, Katariya N, Hewitt W, Moss A, Mulligan D, Heilman R, Chakkera H, Hamawi K, Khamash H, Beck G, Reddy K. Single Center Review of Seroconversion Rate and Clinical Outcomes of Kidney Transplant Recipients from Center for Disease Control (CDC) High Risk Donors. Transplantation 2012, 94: 141. DOI: 10.1097/00007890-201211271-00260.Peer-Reviewed Original ResearchA Consolidated Biovigilance System for Blood, Tissue and Organs: One Size Does Not Fit All
Pruett TL, Blumberg EA, Cohen DJ, Crippin JS, Freeman RB, Hanto DW, Mulligan DC, Green MD. A Consolidated Biovigilance System for Blood, Tissue and Organs: One Size Does Not Fit All. American Journal Of Transplantation 2012, 12: 1099-1101. PMID: 22487495, DOI: 10.1111/j.1600-6143.2011.03907.x.Peer-Reviewed Original ResearchConceptsOrgan transplant recipientsLimited organ availabilityPublic health servicesTransplant recipientsDonor testingOrgan availabilityWaiting listClinical practiceHealth servicesFormal recommendationsTransfer of organsDisease transmissionBloodOrgansOverall benefitTissueTransplantationSupport effortsRecipients
2010
SUBCLINICAL ACUTE REJECTION IS ASSOCIATED WITH INFERIOR GRAFT SURVIVAL IN KIDNEY TRANSPLANT RECIPIENTS ON RAPID STEROID WITHDRAWAL
Heilman R, Davarapalli Y, Chakkera H, Mekeel K, Moss A, Williams J, Hamawi K, Mazur M, Mulligan D, Reddy K. SUBCLINICAL ACUTE REJECTION IS ASSOCIATED WITH INFERIOR GRAFT SURVIVAL IN KIDNEY TRANSPLANT RECIPIENTS ON RAPID STEROID WITHDRAWAL. Transplantation 2010, 90: 176. DOI: 10.1097/00007890-201007272-00341.Peer-Reviewed Original Research
2009
Living donor liver transplantation and donor graft size: How small can we go to reduce risk to the donor and what is the cost to the recipient?
Mulligan D. Living donor liver transplantation and donor graft size: How small can we go to reduce risk to the donor and what is the cost to the recipient? Liver Transplantation 2009, 15: 1392-1394. PMID: 19877257, DOI: 10.1002/lt.21922.Peer-Reviewed Original ResearchUse of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K, Heilman RL, Mazur MJ, Chakkera HA, Mulligan DC, Moss AA, Mekeel KL, Reddy KS. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report. Clinical Transplants 2009, 407-14. PMID: 20524306.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdultAgedAlemtuzumabAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmBoronic AcidsBortezomibCreatinineFemaleGraft RejectionHLA AntigensHumansImmunoglobulins, IntravenousImmunosuppressive AgentsIsoantibodiesKidney TransplantationMaleMiddle AgedProtease InhibitorsPyrazinesRituximabTreatment Outcome
2008
RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY
Moss A, Heilman R, Chakkera H, Mazur M, Petrides S, Wosniak E, Mekeel K, Mulligan D, Reddy K. RISK FACTORS FOR ANTIBODY MEDIATED REJECTION (AMR) IN KIDNEY TRANSPLANT (KTX) RECIPIENTS WITH POSITIVE CDC B-CELL / FLOW CYTOMETRY CROSSMATCH (CXM) TREATED WITH LOE DOSE INTRAVENOUS IMMUNOGLOBULIN (IVIG) AND RATG THERAPY. Transplantation 2008, 86: 591-592. DOI: 10.1097/01.tp.0000330970.94094.7a.Peer-Reviewed Original Research
2007
Coccidioidomycosis in healthy persons evaluated for liver or kidney donation
Blair JE, Mulligan DC. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transplant Infectious Disease 2007, 9: 78-82. PMID: 17313480, DOI: 10.1111/j.1399-3062.2006.00179.x.Peer-Reviewed Original ResearchConceptsDonor-derived coccidioidomycosisKidney donationTransplant recipientsHealthy personsDonor candidatesOrgan donor candidatesRisk of transmissionProphylaxis protocolLiver donationFourth patientCoccidioidal antibodiesPossible liverCoccidioidomycosisFungal infectionsCoccidioides speciesRecipientsFurther studiesPatientsLiverRiskDonationProphylaxisUnique challengesInfectionPrevalence
2006
THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY.
Moss A, Heilman R, Mazur M, Chakkera H, Wozniak E, Post D, Mulligan D, Reddy K. THE INFLUENCE OF DONOR-SPECIFIC ANTIBODIES IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B-CELL/FLOW CYTOMETRY CROSSMATCH TREATED WITH LOW DOSE INTRAVENOUS IMMUNOGLOBULIN AND ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY. Transplantation 2006, 82: 292. DOI: 10.1097/00007890-200607152-00679.Peer-Reviewed Original ResearchAnti-thymocyte globulin induction therapyLow-dose intravenous immunoglobulinDose intravenous immunoglobulinFlow cytometry crossmatchDonor-specific antibodiesKidney transplant recipientsCytometry crossmatchInduction therapyIntravenous immunoglobulinTransplant recipientsCrossmatchTherapyImmunoglobulinRecipientsAntibodiesCLINICAL VARIABLES ASSOCIATED WITH GRAFT FIBROSIS (GF) ON 12 MONTH PROTOCOL BIOPSY IN KIDNEY TRANSPLANT RECIPIENTS ON STEROID AVOIDANCE IMMUNOSUPPRESSION (SA).
Heilman R, Reddy K, Chakkera H, Mazur M, Moss A, Williams J, Colby T, Petrides S, Mulligan D. CLINICAL VARIABLES ASSOCIATED WITH GRAFT FIBROSIS (GF) ON 12 MONTH PROTOCOL BIOPSY IN KIDNEY TRANSPLANT RECIPIENTS ON STEROID AVOIDANCE IMMUNOSUPPRESSION (SA). Transplantation 2006, 82: 461-462. DOI: 10.1097/00007890-200607152-01187.Peer-Reviewed Original ResearchRESOURCE UTILIZATION IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B CELL, FLOW B AND/OR T CELL CROSS MATCH TREATED WITH LOW DOSE IVIG AND THYMOGLOBULIN® INDUCTION THERAPY.
Post D, Moss A, Mulligan D, Heilman R, Mazur M, Chakkera H, Reddy K. RESOURCE UTILIZATION IN KIDNEY TRANSPLANT RECIPIENTS WITH POSITIVE CDC B CELL, FLOW B AND/OR T CELL CROSS MATCH TREATED WITH LOW DOSE IVIG AND THYMOGLOBULIN® INDUCTION THERAPY. Transplantation 2006, 82: 668. DOI: 10.1097/00007890-200607152-01815.Peer-Reviewed Original Research
1999
ASSOCIATION OF HEPATITIS C WITH SUBCLINICAL REACTIVATION OF HEPATITIS B VIRAL DNA DETECTED BY POLYMERASE CHAIN REACTION (PCR) IN ALLOGRAFTS OF RECIPIENTS WITH APPARENT IMMUNITY TO HEPATITIS B
Douglas D, Abdelmaleck M, Pasha T, Mulligan D, Persing D, Wiesner R. ASSOCIATION OF HEPATITIS C WITH SUBCLINICAL REACTIVATION OF HEPATITIS B VIRAL DNA DETECTED BY POLYMERASE CHAIN REACTION (PCR) IN ALLOGRAFTS OF RECIPIENTS WITH APPARENT IMMUNITY TO HEPATITIS B. Transplantation 1999, 67: s631. DOI: 10.1097/00007890-199905150-00379.Peer-Reviewed Original Research
1997
Influence of steroid withdrawal on proteinuria in renal allograft recipients
Ghandour FZ, Knauss TC, Mulligan DC, Schulak JA, Hricik DE. Influence of steroid withdrawal on proteinuria in renal allograft recipients. Clinical Transplantation 1997, 11: 395-398. PMID: 9361929, DOI: 10.1111/j.1399-0012.1997.tb00840.x.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnalysis of VarianceAnti-Inflammatory AgentsAzathioprineChi-Square DistributionChronic DiseaseCreatinineCyclosporineFemaleFollow-Up StudiesGlucocorticoidsGraft RejectionHumansImmunosuppressive AgentsKidney TransplantationLinear ModelsLogistic ModelsMaleMiddle AgedMultivariate AnalysisPrednisoneProteinuriaRecurrenceTransplantation, HomologousConceptsSteroid withdrawalUrinary protein excretionAllograft rejectionProtein excretionPrimary renal transplant recipientsAcute allograft rejectionRenal allograft recipientsRenal transplant recipientsChronic allograft rejectionSpot urine specimensAcute rejectionAllograft recipientsSteroid therapyTransplant recipientsClinical variablesUrine creatinineUrine specimensPatientsProteinuriaWithdrawalExcretionRecipientsRejectionCreatinineTransplantation
1995
Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor
Mulligan D, Gentry L, Dombrausky L, Klintmalm G, Nikaein A. Monitoring of allograft recipients for the development of HLA‐specific antibodies: Elimination of OKT3 as a complicating factor. Clinical Transplantation 1995, 9: 438-441. PMID: 8645885, DOI: 10.1111/j.1399-0012.1995.tb00363.x.Peer-Reviewed Original ResearchConceptsOKT3 MoAbPatient seraPanel reactive antibody (PRA) assayPositive reactivityAnti-HLA antibodiesHLA-specific antibodiesOKT3 monoclonal antibodyFalse-positive reactivityMismanagement of patientsAllograft recipientsHumoral rejectionTransplant recipientsAntibody assaysRabbit antimouse immunoglobulinAntibody developmentMonoclonal antibodiesMoAbSerumAntibodiesAntimouse immunoglobulinRecipientsComplicating factorsOKT3PatientsImmunoglobulin